Breaking News Instant updates and real-time market news.

JAZZ

Jazz Pharmaceuticals

$154.97

-0.97 (-0.62%)

06:11
04/12/18
04/12
06:11
04/12/18
06:11

Jazz remains high conviction specialty pharma idea at Piper Jaffray

After surveying 25 physicians who treat a significant number of obstructive sleep apnea and narcolepsy patients, Piper Jaffray analyst David Amsellem believes peak U.S. sales potential for Jazz Pharmaceuticals' solriamfetol of at least $400M in the OSA/narcolepsy setting is realistic, "particularly given the sizable portion of patients who do not respond adequately to existing options." Solriamfetol helps position Jazz for annual double-digit EBITDA growth over the next several years, Amsellem tells investors in a research note. He calls Jazz one of his highest conviction specialty pharma ideas. The analyst reiterates an Overweight rating on the shares with a $201 price target.

  • 18

    May

  • 31

    May

  • 20

    Dec

JAZZ Jazz Pharmaceuticals
$154.97

-0.97 (-0.62%)

01/16/18
DBAB
01/16/18
NO CHANGE
Target $170
DBAB
Buy
Jazz Pharmaceuticals price target raised to $170 from $165 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raised his price target for Jazz Pharmaceuticals to $170 after adjusting his model for a lower tax rate and higher spend in 2018. The analyst continues to like the stock based on the "growthy" base business, "strong" leadership, and "deal potential." He keeps a Buy rating on the shares.
03/16/18
LEER
03/16/18
NO CHANGE
Target $180
LEER
Outperform
Jazz survey suggests growing Vyxeos usage, says Leerink
Leerink analyst Ami Fadia says her firm's physician survey indicates adoption of Jazz Pharmaceuticals' Vyxeos is "ramping up nicely especially in the outpatient setting." The analyst remains confident that Vyxeos sales will grow to $150M in 2018, in-line with consensus and at the high-end of management's guidance. She reiterates an Outperform rating on Jazz shares with a $180 price target.
03/19/18
MSCO
03/19/18
UPGRADE
MSCO
Overweight
Jazz Pharmaceuticals upgraded to Overweight from Equal Weight at Morgan Stanley
03/19/18
03/19/18
UPGRADE
Target $183

Overweight
Jazz Pharmaceuticals upgraded to Overweight on expected growth at Morgan Stanley
As previously reported, Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight and raised its price target to $183 from $167. Analyst David Risinger said recent management comments imply conviction in strong 2018 growth prospects and M&A optionality due to the strong balance sheet. The analyst also said potential competitive threats from Avadel (AVDL) to Jazz's Xyrem appear significantly delayed and expects increasing investor enthusiasm for the pipeline, especially key new drug candidates JZP-258 and solriamfetol for wakefulness, which appears to have a best-in-class profile. Risinger has increased confidence in JZP-258 being successful in Phase 3 in early 2019 given management signals that it may not choose to file JZP-507 in mid-2018.

TODAY'S FREE FLY STORIES

FTEO

Fronteo

$16.75

(0.00%)

09:45
11/21/18
11/21
09:45
11/21/18
09:45
Hot Stocks
Breaking Hot Stocks news story on Fronteo »

FRONTEO Inc (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
11/21/18
11/21
09:45
11/21/18
09:45
General news
Existing Home Sales to be reported at 10:00 »

October Existing Home…

09:45
11/21/18
11/21
09:45
11/21/18
09:45
General news
Leading Indicators to be reported at 10:00 »

October Leading…

09:45
11/21/18
11/21
09:45
11/21/18
09:45
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

FL

Foot Locker

$46.10

(0.00%)

09:42
11/21/18
11/21
09:42
11/21/18
09:42
Technical Analysis
Technical Take: Foot Locker slips from earlier highs »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXM

Oxford Industries

$84.74

(0.00%)

09:41
11/21/18
11/21
09:41
11/21/18
09:41
Periodicals
Breaking Periodicals news story on Oxford Industries »

Oxford Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.10

(0.00%)

, GPS

Gap

$24.65

(0.00%)

09:40
11/21/18
11/21
09:40
11/21/18
09:40
Options
Unusually active option classes on open November 21st »

Unusual total active…

FL

Foot Locker

$46.10

(0.00%)

GPS

Gap

$24.65

(0.00%)

MT

ArcelorMittal

$23.41

(0.00%)

ADSK

Autodesk

$122.99

(0.00%)

WLL

Whiting Petroleum

$28.78

(0.00%)

SLV

iShares Silver Trust

$13.45

(0.00%)

DE

Deere

$138.49

(0.00%)

FXI

iShares China Large-Cap ETF

$40.18

(0.00%)

WDC

Western Digital

$45.69

(0.00%)

M

Macy's

$31.96

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 27

    Nov

  • 04

    Dec

  • 04

    Dec

  • 03

    Mar

09:40
11/21/18
11/21
09:40
11/21/18
09:40
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

PULM

Pulmatrix

$0.39

-0.0205 (-5.05%)

09:36
11/21/18
11/21
09:36
11/21/18
09:36
Hot Stocks
Pulmatrix says objectives from Phase 1/1b study of Pulmazole 'successfully met' »

Pulmatrix, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ROST

Ross Stores

$82.65

-8.54 (-9.37%)

09:35
11/21/18
11/21
09:35
11/21/18
09:35
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
11/21/18
11/21
09:35
11/21/18
09:35
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

TGT

Target

$69.05

-8.08 (-10.48%)

09:34
11/21/18
11/21
09:34
11/21/18
09:34
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

ANAB

AnaptysBio

$68.73

0.8 (1.18%)

09:32
11/21/18
11/21
09:32
11/21/18
09:32
Initiation
AnaptysBio initiated  »

JPMorgan sees attractive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, NKE

Nike

$71.13

-1.39 (-1.92%)

09:30
11/21/18
11/21
09:30
11/21/18
09:30
Recommendations
Foot Locker, Nike analyst commentary  »

Foot Locker price target…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

NKE

Nike

$71.13

-1.39 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

CS

Credit Suisse

$11.72

-0.585 (-4.75%)

09:30
11/21/18
11/21
09:30
11/21/18
09:30
Downgrade
Credit Suisse rating change  »

Credit Suisse downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

09:30
11/21/18
11/21
09:30
11/21/18
09:30
General news
The U.S. durables report undershot estimates »

The U.S. durables report…

GPS

Gap

$24.65

-0.79 (-3.11%)

09:26
11/21/18
11/21
09:26
11/21/18
09:26
Recommendations
Gap analyst commentary  »

Gap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

ADI

Analog Devices

$89.12

3.57 (4.17%)

09:25
11/21/18
11/21
09:25
11/21/18
09:25
Recommendations
Analog Devices analyst commentary  »

Analog Devices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

TMUS

T-Mobile

$66.56

-1.45 (-2.13%)

, S

Sprint

$6.08

-0.11 (-1.78%)

09:25
11/21/18
11/21
09:25
11/21/18
09:25
Periodicals
T-Mobile shifts approach to selling Sprint merger to regulators, Bloomberg says »

T-Mobile (TMUS), in a…

TMUS

T-Mobile

$66.56

-1.45 (-2.13%)

S

Sprint

$6.08

-0.11 (-1.78%)

T

AT&T

$29.41

-0.93 (-3.07%)

VZ

Verizon

$59.46

-1.17 (-1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 03

    Dec

  • 04

    Dec

QCOM

Qualcomm

$54.92

0.02 (0.04%)

, AAPL

Apple

$177.10

-8.7 (-4.68%)

09:23
11/21/18
11/21
09:23
11/21/18
09:23
Periodicals
Qualcomm gets Apple's patent claims dismissed, Bloomberg reports »

Qualcomm (QCOM) won bid…

QCOM

Qualcomm

$54.92

0.02 (0.04%)

AAPL

Apple

$177.10

-8.7 (-4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ECOL

US Ecology

$70.69

-1.29 (-1.79%)

09:19
11/21/18
11/21
09:19
11/21/18
09:19
Recommendations
US Ecology analyst commentary  »

US Ecology price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$65.06

-7.9 (-10.83%)

09:18
11/21/18
11/21
09:18
11/21/18
09:18
Recommendations
Jacobs Engineering analyst commentary  »

Jacobs Engineering price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 19

    Feb

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
11/21/18
11/21
09:18
11/21/18
09:18
Options
Overnight activity included 663 trades in SPX and 38 trades in VIX »

663 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGCO

Agco

$57.86

0.5 (0.87%)

09:16
11/21/18
11/21
09:16
11/21/18
09:16
Recommendations
Agco analyst commentary  »

William Blair keeps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$64.45

-6.3 (-8.90%)

09:15
11/21/18
11/21
09:15
11/21/18
09:15
Recommendations
Kohl's analyst commentary  »

Kohl's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.